John Victor Heymach
The University of Texas MD Anderson Cancer Center · 2,506 works · 79,251 citations · h-index 132
Top works
- Comprehensive molecular profiling of lung adenocarcinoma
- Comprehensive genomic characterization of squamous cell lung cancers
- Lung Cancer
- Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
- PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
- Second-Line Treatment of Advanced Non-small Cell Lung Cancer
- Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
- An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
- Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
- Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
- Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
- Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
- Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
- A pan-cancer proteomic perspective on The Cancer Genome Atlas
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy